Association between evolocumab use and slow progression of aortic valve stenosis.
And lipoprotein(a)
Aortic valve stenosis
Evolocumab
Proprotein convertase subtilisin/kexin type 9 inhibitors
Journal
Heart and vessels
ISSN: 1615-2573
Titre abrégé: Heart Vessels
Pays: Japan
ID NLM: 8511258
Informations de publication
Date de publication:
19 Mar 2024
19 Mar 2024
Historique:
received:
31
10
2023
accepted:
28
02
2024
medline:
19
3
2024
pubmed:
19
3
2024
entrez:
19
3
2024
Statut:
aheadofprint
Résumé
No medications have been reported to inhibit the progression of aortic valve stenosis (AS). The present study aimed to investigate whether evolocumab use is related to the slow progression of AS evaluated by serial echocardiography. This was a retrospective observational study from 2017 to 2022 at Yokohama City University Medical Center. Patients aged ≥ 18 with moderate AS were included. Exclusion criteria were (1) mild AS; (2) severe AS defined by maximum aortic valve (AV) velocity ≥ 4.0 m/s; and/or (3) no data of annual follow-up echocardiography. The primary endpoint was the association between evolocumab use and annual changes in the maximum AV-velocity or peak AV-pressure gradient (PG). A total of 57 patients were enrolled: 9 patients treated with evolocumab (evolocumab group), and the other 48 patients assigned to a control group. During a median follow-up of 33 months, the cumulative incidence of AS events (a composite of all-cause death, AV intervention, or unplanned hospitalization for heart failure) was 11% in the evolocumab group and 58% in the control group (P = 0.012). Annual change of maximum AV-velocity or peak AV-PG from the baseline to the next year was 0.02 (- 0.18 to 0.22) m/s per year or 0.60 (- 4.20 to 6.44) mmHg per year in the evolocumab group, whereas it was 0.29 (0.04-0.59) m/s per year or 7.61 (1.46-16.48) mmHg per year in the control group (both P < 0.05). Evolocumab use was associated with slow progression of AS and a low incidence of AS events in patients with moderate AS.
Identifiants
pubmed: 38499696
doi: 10.1007/s00380-024-02386-6
pii: 10.1007/s00380-024-02386-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Springer Nature Japan KK, part of Springer Nature.
Références
Dweck MR, Boon NA, Newby DE (2012) Calcific aortic stenosis: a disease of the valve and the myocardium. J Am Coll Cardiol 60(19):1854–1863
doi: 10.1016/j.jacc.2012.02.093
pubmed: 23062541
Coffey S, Cox B, Williams MJA (2014) The prevalence, incidence, progression, and risks of aortic valve sclerosis: a systematic review and meta-analysis. J Am Coll Cardiol 63(25):2852–2861
doi: 10.1016/j.jacc.2014.04.018
pubmed: 24814496
Osnabrugge RLJ, Mylotte D, Head SJ, Mieghem NMV, Nkomo VT, LeReum CM, Bogers AJJC, Piazza N, Kappetein AP (2013) Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. J Am Coll Cardiol 62(11):1002–1012
doi: 10.1016/j.jacc.2013.05.015
pubmed: 23727214
Ross J, Braunwald E (1968) Aortic stenosis. Circulation 38(1):61–67
pubmed: 4894151
Chan KL, Teo K, Dumesnil JG, Ni A, Tam J (2010) Effect of lipid lowering with rosuvastatin on progression of aortic stenosis. Circulation 121(2):306–314
doi: 10.1161/CIRCULATIONAHA.109.900027
pubmed: 20048204
Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA (2005) A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 352(23):2389–2397
doi: 10.1056/NEJMoa043876
pubmed: 15944423
Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R (2008) Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 359(13):1343–2135
doi: 10.1056/NEJMoa0804602
pubmed: 18765433
Kaiser Y, van der Toorn JE, Singh SS, Zheng KH, Kavousi M, Sijbrands EJG, Stroes ESG, Vernooij MW, de Rijke YB, Boekholdt SM, Bos D (2022) Lipoprotein(a) is associated with the onset but not the progression of aortic valve calcification. Eur Heart J 43(39):3960–3967
doi: 10.1093/eurheartj/ehac377
pubmed: 35869873
pmcid: 9840475
Kronenberg F (2022) Lipoprotein(a) and aortic valve stenosis: work in progress. Eur Heart J 43(39):3968–3970
doi: 10.1093/eurheartj/ehac436
pubmed: 35979826
Zheng KH, Tsimikas S, Pawade T, Kroon J, Jenkins WSA, Doris M, White AC, Timmers NKLM, Hjortnaes J, Rogers MA, Aikawa E, Arsenault BJ, Witztum J, Newby DE, Koschinsky ML, Fayad ZA, Stroes ESG, Boekholdt SM, Dweck MR (2019) Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis. J Am Coll Cardiol 73(17):2150–2162
doi: 10.1016/j.jacc.2019.01.070
pubmed: 31047003
pmcid: 6494952
Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, Kerr KF, Pechlivanis S, Budoff MJ, Harris TB, Malhotra R, O’Brien KD, Kamstrup PR, Nordestgaard BG, Tybjaerg-Hansen A, Allison MA, Aspelund T, Criqui MH, Heckbert SR, Hwang SJ, Liu Y, Sjogren M, van der Pals J, Kälsch H, Mühleisen TW, Nöthen MM, Cupples LA, Caslake M, Di Angelantonio E, Danesh J, Rotter JI, Sigurdsson S, Wong Q, Erbel R, Kathiresan S, Melander O, Gudnason V, O’Donnell CJ, Post WS (2013) Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 368(6):503–512
doi: 10.1056/NEJMoa1109034
pubmed: 23388002
pmcid: 3766627
Kiyosue A, Honarpour N, Kurtz C, Xue A, Wasserman SM, Hirayama A (2016) A phase 3 study of evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk. Am J Cardiol 117(1):40–47
doi: 10.1016/j.amjcard.2015.10.021
pubmed: 26547291
Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL (2020) Statin therapy increases lipoprotein(a) levels. Eur Heart J41(24):2275–2284
doi: 10.1093/eurheartj/ehz310
O’Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, Im KA, Pineda AL, Wasserman SM, Češka R, Ezhov MV, Jukema JW, Jensen HK, Tokgözoğlu SL, Mach F, Huber K, Sever PS, Keech AC, Pedersen TR, Sabatine MS (2019) Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation 139(12):1483–1492
doi: 10.1161/CIRCULATIONAHA.118.037184
pubmed: 30586750
Bergmark BA, O’Donoghue ML, Murphy SA, Kuder JF, Ezhov MV, Češka R, Gouni-Berthold I, Jensen HK, Tokgozoglu SL, MacH F, Huber K, Gaciong Z, Lewis BS, Schiele F, Jukema JW, Pedersen TR, Giugliano RP, Sabatine MS (2020) An exploratory analysis of proprotein convertase subtilisin/kexin type 9 inhibition and aortic stenosis in the FOURIER Trial. JAMA Cardio 5(6):709–713
doi: 10.1001/jamacardio.2020.0728
Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D, Conradi L, De Bonis M, De Paulis R, Delgado V, Freemantle N, Gilard M, Haugaa KH, Jeppsson A, Jüni P, Pierard L, Prendergast BD, Sadaba JR, Tribouilloy C, Wojakowski W, Neumann FJ, Myers P, Abdelhamid M, Achenbach S, Asteggiano R, Barili F, Borger MA, Carrel T, Collet JP, Foldager D, Habib G, Hassager C, Irs A, Iung B, Jahangiri M, Katus HA, Koskinas KC, Massberg S, Mueller CE, Nielsen JC, Pibarot P, Rakisheva A, Roffi M, Rubboli A, Shlyakhto E, Siepe M, Sitges M, Sondergaard L, Sousa-Uva M, Tarantini G, Zamorano JL, Benchabi Y, Chilingaryan A, Metzler B, Rustamova Y, Shumavets V, Lancellotti P, Smajic E, Trendafilova-Lazarova D, Samardzic J, Karakyriou M, Palecek T, Dahl JS, Meshaal MS, Palm K, Virtanen M, Bouleti C, Bakhutashvili Z, Boutsikou M, Kertész AB, Danielsen R, Topilsky Y, Golino P, Tuleutayev R, Elezi S, Kerimkulova A, Rudzitis A, Glaveckaite S, Sow R, Demarco DC, Bulatovic N, Aouad A, Van Den Brink R, Antova E, Beitnes JO, Ochala A, Ribeiras R, Vinereanu D, Irtyuga O, Ivanovic B, Simkova I, Gomez AG, Sarno G, Pedrazzini GB, Bsata W, Zakhama L, Korkmaz L, Cherniuk S, Khanji MY, Sharipov I, Baigent C, Aboyans V, Antoniou S, Arbelo E, Baumbach A, Čelutkiene J, Cikes M, Falk V, Fauchier L, Gale CP, Halvorsen S, Jaarsma T, Konradi A, Kotecha D, Landmesser U, Lewis BS, Linhart A, Løchen ML, Neubeck L, Petersen SE, Prescott E, Touyz RM, Galletti L, Hazekamp M, Licht P, Perier P, Prager R, Roessner E, Tsagakis K, Zientara A (2022) 2021 ESC/EACTS guidelines for the management of valvular heart disease developed by the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 43(7):561–632
doi: 10.1093/eurheartj/ehab395
pubmed: 34453165
Baumgartner H, Hung J, Bermejo J, Chambers JB, Edvardsen T, Goldstein S, Lancellotti P, LeFevre M, Miller F, Otto CM (2017) Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr 30(4):372–392
doi: 10.1016/j.echo.2017.02.009
pubmed: 28385280
Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD, Mickley H, Crea F, Van De Werf F, Bucciarelli-Ducci C, Katus HA, Pinto FJ, Antman EM, Hamm CW, De Caterina R, Januzzi JL, Apple FS, Garcia MAA, Underwood SR, Canty JM, Lyon AR, Devereaux PJ, Zamorano JL, Lindahl B, Weintraub WS, Newby LK, Virmani R, Vranckx P, Cutlip D, Gibbons RJ, Smith SC, Atar D, Luepker RV, Robertson RM, Bonow RO, Steg PG, O’Gara PT, Fox KAA, Hasdai D, Aboyans V, Achenbach S, Agewall S, Alexander T, Avezum A, Barbato E, Bassand JP, Bates E, Bittl JA, Breithardt G, Bueno H, Bugiardini R, Cohen MG, Dangas G, De Lemos JA, Delgado V, Filippatos G, Fry E, Granger CB, Halvorsen S, Hlatky MA, Ibanez B, James S, Kastrati A, Leclercq C, Mahaffey KW, Mehta L, Müller C, Patrono C, Piepoli MF, Piñeiro D, Roffi M, Rubboli A, Sharma S, Simpson IA, Tendera M, Valgimigli M, Van Der Wal AC, Windecker S (2019) Fourth universal definition of myocardial infarction (2018). Eur Heart J 40(3):237–269
doi: 10.1093/eurheartj/ehy462
pubmed: 30165617
Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, Kitzman DW, Otto CM (1997) Clinical factors associated with calcific aortic valve disease. J Am Coll Cardiol 29(3):630–634
doi: 10.1016/S0735-1097(96)00563-3
pubmed: 9060903
Rajamannan NM, Bonow RO, Rahimtoola SH (2007) Calcific aortic stenosis: an update. Nat Clin Pract Cardiovasc Med 4(5):254–262
doi: 10.1038/ncpcardio0827
pubmed: 17457349
Luis MM, Sandra FR, José LZ, Isabel MB, Luis FA, Francisco RG, Nalini MR (2007) Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 49(5):554–561
doi: 10.1016/j.jacc.2006.07.072
Zhao Y, Nicoll R, He YH, Henein MY (2016) The effect of statins on valve function and calcification in aortic stenosis: a meta-analysis. Atherosclerosis 246:318–324
doi: 10.1016/j.atherosclerosis.2016.01.023
pubmed: 26828749
Kensuke M, Olivier M, Patrick O (2023) Contemporary issues and lifetime management in patients underwent transcatheter aortic valve replacement. Cardiovasc Interv Ther 38(3):275–286
doi: 10.1007/s12928-023-00924-z
Rajamannan NM, Evans FJ, Aikawa E, Grande-Allen KJ, Demer LL, Heistad DD, Simmons CA, Masters KS, Mathieu P, O’Brien KD, Schoen FJ, Towler DA, Yoganathan AP, Otto CM (2011) Calcific aortic valve disease: not simply a degenerative process. Circulation 124(16):1783–1791
doi: 10.1161/CIRCULATIONAHA.110.006767
pubmed: 22007101
pmcid: 3306614
Mazière C, Louvet L, Gomila C, Kamel S, Massy Z, Mazière JC (2009) Oxidized low density lipoprotein decreases Rankl-induced differentiation of osteoclasts by inhibition of Rankl signaling. J Cell Physiol 221(3):572–578
doi: 10.1002/jcp.21886
pubmed: 19725047
Derwall M, Malhotra R, Lai CS, Beppu Y, Aikawa E, Seehra JS, Zapol WM, Bloch KD, Yu PB (2012) Inhibition of bone morphogenetic protein signaling reduces vascular calcification and atherosclerosis. Arterioscler Thromb Vasc Biol 32(3):613–662
doi: 10.1161/ATVBAHA.111.242594
pubmed: 22223731
Demer L, Tintut Y (2011) The roles of lipid oxidation products and receptor activator of nuclear factor-kappa B signaling in atherosclerotic calcification. Circ Res 108(12):1482
doi: 10.1161/CIRCRESAHA.110.234245
pubmed: 21659652
pmcid: 3128471
Hung MY, Witztum JL, Tsimikas S (2014) New therapeutic targets for calcific aortic valve stenosis: the lipoprotein(a)-lipoprotein-associated phospholipase A2-oxidized phospholipid axis. J Am Coll Cardiol 63(5):478–480
doi: 10.1016/j.jacc.2013.08.1639
pubmed: 24161316
Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, Fras Z, Goodman SG, Halvorsen S, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Moriarty PM, Moryusef A, Pordy R, Roe MT, Sinnaeve P, Tsimikas S, Vogel R, White HD, Zahger D, Zeiher AM, Steg PG, Schwartz GG (2020) Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome. J Am Coll Cardiol 75(2):133–144
doi: 10.1016/j.jacc.2019.10.057
pubmed: 31948641
Willner N, Prosperi-Porta G, Lau L, Nam Fu AY, Boczar K, Poulin A, Di Santo P, Unni RR, Visintini S, Ronksley PE, Chan KL, Beauchesne L, Burwash IG, Messika-Zeitoun D (2023) Aortic stenosis progression: a systematic review and meta-analysis. JACC Cardiovasc Imaging 16(3):314–328
doi: 10.1016/j.jcmg.2022.10.009
pubmed: 36648053